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Flaviviruses are responsible for a number of important mosquito-borne diseases of man and animals globally. The short vireamic
period in infected hosts means that serological assays are often the diagnostic method of choice. This paper will focus on
the traditional methods to diagnose ﬂaviviral infections as well as describing the modern rapid platforms and approaches for
diagnostic antigen preparation.
1.Introduction
Flaviviruses are responsible for a number of important mos-
quito-borne diseases of man and animals globally. The Fla-
vivirus genus, consists of 50 species and 23 viral subtypes
[1], which are further separated into 12 groups based on
phylogenetic analysis of the NS5 gene [2], as well as antigenic
and ecological similarities [1]. Members of the globally dis-
tributed Japanese encephalitis serocomplex, include viruses
such as West Nile virus (WNV), Murray Valley encephalitis
virus (MVEV), St. Louis encephalitis virus (SLEV), and
Japanese encephalitis virus (JEV) [1]. Other serocomplexes
include yellow fever virus (YFV), tick-borne encephalitis
virus (TBEV), and Dengue virus (DENV) [3, 4]. Of recent
concern is the rapid spread of a particularly virulent strain of
WNV through North, Central, and South America [5]. This
mosquito-borne virus can cause a fatal form of encephalitis
in humans, birds, and horses [6, 7] and since its introduction
toAmericain1999,ithascausedtensofthousandsofclinical
cases and thousands of deaths in humans and horses [8, 9].
More recently, a WNV outbreak occurred in Europe during
2010 and 2011, where it has been reported that there were
197 humans cases of neuroinvasive disease caused by WNV
in 2010 and a further 31 cases between July and August 2011
[10,11]. In 2011 there wasalsoanoutbreakof encephalitis in
horses caused by the WNV subtype, Kunjin virus (KUNV),
in the south-eastern areas of Australia [12].
The viruses of the JEV serocomplex are maintained in
nature in a cycle involving mosquitoes and in most cases,
birds as the vertebrate host. However, pigs usually serve as an
amplifying host during outbreaks of JEV. While horses and
humanscanbecomeinfected,theyareclassiﬁedas“dead-end
hosts” as the viraemia is usually insuﬃcient to subsequently
infect feeding mosquitoes [13]. Similarly, this low level of
viraemia, particularly at the time of clinical presentation for
both humans and horses limits the likelihood of detecting
viral antigen or RNA. Thus, diagnosis of ﬂaviviral infec-
tions is commonly achieved using serological assays such
as plaque reduction neutralization tests (which are time
consumingandrequirethehandlingoflivevirus)andELISA.
While assays such as ELISA are ideal for high-throughput
screening, they are not readily adaptable to rapid, pen-side
testing. The cross-reactive nature of the immune response
to ﬂaviviral infections also causes problems for the speciﬁc
diagnosis of ﬂaviviral infections and the development of
rapid immunoassays [14].
There have been numerous approaches to improve the
speciﬁcity of serological-based ﬂavivirus diagnostic assays.
These include preparing sub-unit antigens, identifying
immunogenic peptides and competitive blocking assays.2 Journal of Biomedicine and Biotechnology
Although this review will focus predominantly on the ap-
proaches used to improve diagnostic assays for WNV, these
approaches are applicable to the other viruses of the JEV
serocomplex, since they have similar ecology, epidemiology
and pathology.
2. Considerations for the Development of
FlavivirusDiagnosticAssays
2.1. Viraemia and Antibody Development during Flavivirus
Infection. In humans, clinical symptoms of WNV disease,
such as a mild febrile illness with fever, headache, and fatigue
[15], generally appear two to 14 days postinfection [16–
18]. However, in some infections acquired through blood
transfusion, symptoms were not observed for up to 22 days
[18]. After a laboratory-acquired infection of the Australian
WNV subtype, KUNV, the infected individual developed
symptoms 9 days after the presumed infection date [19]. Less
than 1% of WNV infections result in neurological disease,
whichcanbefatal[20–23].Althoughviraemiacanbepresent
at symptom onset during ﬂaviviral infections, the delay in
most patients presenting to a medical practitioner [22, 24]
means that detection of blood-borne virus or viral RNA
can be diﬃcult. While the exact time from the bite of a
WNV-infected mosquito to detectable levels of circulating
viral RNA in the patient’s blood is not known [25], an
early study involving the inoculation of terminally ill cancer
patients with Egyptian strains of WNV, indicated that virus
could be detected in the blood one to two days postinfection
[26]. Following the laboaratory-acquired infection of the
individual with KUNV, the virus was isolated 8–10 days
postinfection [19]. Screening of viraemic blood donors in
the USA by Busch et al. (2008), revealed persistence of
viral RNA for about 19 days, as determined by nucleic acid
ampliﬁcation testing [25]. In this study, IgM seroconversion
occurred at about four days after the detection of RNA.
However,intwolaboratory-acquiredinfections,IgMwasnot
detected until 13–17 days postinfection [16]. Interestingly,
in one study, anti-WNV IgM was shown to persist for an
average of 156 days [25] and was present for well over a year
[27], rendering IgM serological assays unable to diﬀerentiate
past and recent infections. IgG seroconversion occurs one
to four days after the appearance of IgM [25, 28]. In a
study exploring the IgM and IgG responses to JEV infection,
similar kinetics to those reported for WNV were observed
[29]. In this study, of the 32 patients that were admitted to
hospital with acute encephalitis, 53% of the JEV seropositive
patients had IgM present at admission, and all had IgM by
7 days postadmission. By day 180, 39% of the patients still
had detectable IgM. The IgG response peaked 30 days after
admission and was still detectable in half of the cases after
180 days.
WNVinfectionofhorsesintheUSAhashadasigniﬁcant
eﬀect on the equine industry [30]. Approximately 10% of
infected horses show signs of disease [13]. The symptoms
are generally neurological and include ataxia, paralysis,
and altered behaviour [31]. Experimental infections have
induced a virus neutralising immune response by seven to
12 days postinfection [13, 32, 33] and clear IgM seroconver-
sion around day seven postinfection [13]. The detection of
virus in the blood of the experimentally infected horses in
the study by Bunning et al. (2002) [13]o c c u r r e df r o md a y s1
to 3 postinfection and persisted until day 5 or 6 for all of the
horses, except for one which only had detectable viraemia
on days 3 and 4. Only one of the horses developed clinical
signs of disease, which occurred on day 8 postinfection, and
thus outside the window for virus detection, highlighting
the requirement for antibody-based diagnostic assays for
horses as well. Infection of horses with KUNV or MVEV
can also cause a neurological disease [12, 34–36], although
experimental infection of a limited number of horses with
MVEV failed to induce clinical symptoms [37]. In this
study, ﬁve of the 11 experimentally infected animals had
detectable levels of the virus in their blood from day 1 to
day 5 postinfection. All of the horses developed an antibody
response to MVEV seven to fourteen days postinfection.
2.2. Geographical Distribution of the Pathogenic Flaviviruses
and Considerations for Serological Diagnostic Assay Speciﬁcity.
The presence of ﬂaviviruses of the JEV serocomplex within
the same geographic regions poses problems for the diagnos-
tic speciﬁcity of serological assays due to the development of
cross-reactive antibodies during ﬂaviviral infections [4]. In
North America, the presence of WNV and SLEV complicates
serological speciﬁcity when diagnosing infections in humans
and horses [38, 39]. In South America, in addition to WNV
and SLEV, ﬂaviviruses that should also be considered when
testing equine sera include Ilheus virus and Bussuquara
virus, although recent serosurveys have not found any
equines with Bussuquara virus-neutralising antibodies [40–
42]. In Europe, the African ﬂavivirus, Usutu virus, was
detected for the ﬁrst time in sentinel horses, chickens, and
birds during surveillance for WNV in 2008 and 2009 [43]
and has since caused neurological disorders in patients in
Italy [44, 45]. WNV caused a major outbreak of encephalitis
in Greece in 2010 and cross-reactivity between WNV and
DENV was observed when testing patient sera from this
outbreak [46].
Australia has the largest number of diﬀerent JEV sero-
group species in the world. There have been incursions of
JEV in the northern areas of the continent, while in recent
years there have been outbreaks of dengue virus in northern
Queensland. Kunjin virus is endemic in Northern Australia
and in 2011 there was an outbreak of equine encephalitis
with a 10–15% case fatality rate, caused by a virulent KUNV
strain in South Eastern Australia [12]. In addition to KUNV
and JEV, humans and horses also develop infections to
MVEVandKokoberra,whichcanalsocomplicateserological
diagnosis [34–37] (May et al., manuscript under revision).
Indeed,sequentialexposuretodiﬀerentﬂavivirusesenhances
theproductionofﬂaviviruscross-reactiveantibodies,leading
to false positives in some serological assays [47].
Prior vaccination against one or more ﬂaviviruses must
also be considered when interpreting assay speciﬁcity. Hu-
man vaccines are available for tick-borne encephalitis virus,
JEV and YFV and a recent study showed cross-neutralisationJournal of Biomedicine and Biotechnology 3
of DENV, WNV, and/or louping ill virus (LIV, which is a
member of the TBEV serocomplex) by human serum sam-
ples taken following vaccination against TBEV and JEV [48].
The likelihood of samples cross-neutralising DENV and
WNV was increased if the individuals were also vaccinated
against YFV, in addition to JEV and TBEV. False positives
in WNV assays have also been documented when assessing
serum from JEV-vaccinated horses [49].
2.3. The Immunogenic Flavivirus Proteins. The ﬂavivirus
virion is spherical, enveloped, and approximately 500 ˚ Ai n
diameter [50]. It consists of a host-derived lipid bilayer con-
taining 180 copies of the envelope (E) and membrane (M)
proteins, which are arranged in a herringbone pattern [50,
51].Thisenvelopesurroundsanucleocapsidcorewhichcon-
tains the single stranded, positive sense RNA genome of ap-
proximately 11kb [52, 53]. The genome contains a single
openreadingframe(ORF),boundedby5  and3  untranslat-
ed regions [54]. The ORF is translated as a single polypro-
tein of three structural and seven nonstructural proteins,
which are cleaved by viral and cellular proteases [55].
The immunodominant antigens during WNV infection
are the E, prM, and NS1 proteins [56–62], although antibod-
ies to the nonstructural proteins NS3 and NS5 have also been
detected in humans [63, 64].
2.3.1. The Envelope Protein. The E protein is the dominant
proteinpresentonthesurfaceoftheﬂavivirusvirion[50,51].
It is a major target for neutralising antibodies [65–67]. The
E protein monomer is divided into three domains. Domain
I (DI) features an eight-stranded β barrel [51, 68, 69] and in
many of the recent virulent WNV strains isolated, it contains
the sole E protein N-linked glycan moiety [53]. Domain II
(DII) contains the highly conserved fusion peptide [70]a n d
Domain III (DIII) is an immunoglobulin-like structure [71]
which is likely to participate in receptor binding [68, 72].
WNV E protein neutralising epitopes have been well-
deﬁned and map to all three domains [71, 73–75]. The ma-
jority of potent neutralising monoclonal antibodies (mAb)
bind DIII, in particular residues 302–309 and 330–333 of
the lateral ridge [71, 75–77]. Importantly, these epitopes are
more likely to be type speciﬁc, but are not the target of
mostantibodiesgeneratedduringWNVinfectionofhumans
and horses [59, 74]. Recent studies have revealed that most
antibodies are directed to DII epitopes [59], which tend to be
highly cross-reactive [78, 79].
2.3.2. prM/M. prM is a 20–25kDa precursor to M protein
and is present on immature, noninfectious particles [80, 81]
and to alesser extent on secreted infectious particles [82, 83].
During the virus maturation process, cleavage of prM by the
cellular protease, furin, at a highly conserved cleavage site
[84],resultsinthereleaseofthesinglyglycosylatedprprotein
[84–86]. Furin cleavage of prM occurs only after exposure of
the protein to low pH in the late endosomes [84].
While the crystal structure for WNV prM has not yet
been determined, DENV prM was recently crystalised and
the structure elucidated [87]. This study revealed that the pr
protein consisted of seven beta strands and conﬁrmed that
the protein structure was stabilised by the presence of three
disulphide bonds. The pr peptide covers the E protein fusion
peptide loop (DII) in the immature virus, thus pre-venting
premature fusion of the virus particle with the host cell
membrane during transport through the trans-Golgi net-
work [80, 88].
Antibodies to prM are generated during ﬂaviviral infec-
tion [59, 62, 89]. Western blot analysis using whole viral an-
tigen and WNV-immune horse serum clearly demonstrates
that the majority of antibodies generated during WNV
infection are directed to the E and prM proteins [62]. Gen-
erally,theanti-prMantibodiesdonotelicitpotentvirusneu-
tralisation in vitro. However, they can be protective in vivo
[90–93]. A study by Cardosa et al. (2002) suggested that
antibodies to prM may be virus speciﬁc, due to the ability
of this antigen to diﬀerentiate DENV and JEV infections in
humans [89]. However, in another study, immune serum
from SLEV- and WNV-infected humans showed cross-
r e a c t i v i t yb e t w e e nW N Va n dS L E Vp r M[ 94]. Nevertheless,
prM may be a potential candidate antigen for incorporation
into species-speciﬁc assays.
2.3.3. NS1. NS1 is a glycosylated, nonstructural protein, of
about 48kDa which has a highly conserved structure that
is stabilised by six disulﬁde bridges [95, 96]. To date, there
has been no success in crystallising NS1. However, elec-
tron microscopy has recently provided some insight into the
structure of the hexameric secreted form of NS1 [97, 98].
NS1 is thought to have an important role in RNA replication
[99–102] and has been colocalised with the double-stranded
RNA replicative form [100]. NS1 also appears to have a
role in immune evasion, as it has been shown to attenuate
complement activation [103] .W h i l eal a r g ea m o u n to fN S 1
remainsintheinfectedcell[104],itisalsoactivelysecretedat
relatively high levels [104–107]. This secreted protein stim-
ulates a strong [108–110], protective, but non-neutralising
antibody response [111–113] and it has been targeted by
serological assays [56, 58, 114–116] .T h e r eh a v ea l s ob e e n
numerous mAbs generated to this protein [111, 117–120],
some of which have been incorporated into antigen capture
assays for the early detection of virus infection [104, 121].
3. Serological Diagnosisof
FlaviviralInfections
3.1. Traditional Approaches
3.1.1. Plaque Reduction Neutralisation Tests. The Plaque
Reduction Neutralisation Test (PRNT) is the gold standard
for the serological diagnosis of ﬂaviviral infections. PRNT
and virus neutralisation tests (VNT) assess for serum anti-
bodies that bind to the viral envelope protein and prevent
virus entry into the cell (normally Vero cells for ﬂavivirus
assessment) in vitro [122, 123]. In PRNT, neutralisation of
the virus by antibodies in the infected patient’s serum is
evidenced by a reduction of plaques relative to the serum
dilution. Virus neutralisation in VNTs results in the absence,4 Journal of Biomedicine and Biotechnology
or, decrease in visible cytopathic eﬀect in the cell monolayer.
PRNT can be highly speciﬁc, although the accuracy of inter-
pretation of the results depends upon simultaneous assess-
ment against ﬂaviviruses endemic to a given area, to allow
for comparison of end-point titres. Other disadvantages of
these tests are that they are labour intensive, require skilled
personnel, a minimum of ﬁve days to perform, and the
handling of live virus, whichrequires a BSL-3 (Biosafety level
3) facility (Table 1).
3.1.2. Haemagglutination Inhibition Assay. Haemagglutina-
tion and Haemagglutination Inhibition assays (HI) have
been widely used for the detection of arthropod-borne
viruses and the antibodies developed to these viruses, re-
spectively [14, 124]. These assays exploit the ability of the
envelope glycoprotein to bind and agglutinate avian eryth-
rocytes so that they form a visible lattice in a U-bottom
microtitre plate. In the HI assay, antibodies from infected
individuals prevent the agglutination of the erythrocytes,
which subsequently form a pellet. While the HI assay was
used extensively in the past for ﬂavivirus serology, this
technique has now been largely superseded, in favour of
assays with better sensitivity and speciﬁcity, but is still used
in some instances for surveillance [125, 126]. The advantages
of HI assays are that providing avian red blood cells are
available, the assays can be performed with minimal training
and equipment and the antigen used can be inactivated by a
simple extraction process. However, as for PRNT, there is a
requirement for the simultaneous assessment for ﬂaviviruses
endemic for the area and multiple diﬀerent pH buﬀers are
requiredforeachdiﬀerentantigen.Aconstantsupplyoffresh
avian red blood cells is also necessary and there is a high level
of cross-reactivity amongst the ﬂaviviruses [127].
3.1.3. Immunoﬂuorescence Assay. The Immunoﬂuorescence
assay (IFA) can be used to diﬀerentiate the IgM and
IgG responses to ﬂaviviral infection. It involves incubating
patient serum with glass slides, upon which are ﬁxed
ﬂavivirus-infected cells. The patient’s virus-speciﬁc antibod-
ies are then detected with a ﬂuorophore-conjugated antispe-
cies IgM or IgG immunoglobulin. The beneﬁt of this assay is
thatpreﬁxedslidescanbestoredat4◦CandaBSL-3facilityis
notrequiredtoperformtheassayandresultscanbeobtained
quickly, particularly due to the commercialisation of IFA
kits (e.g., Focus Diagnostics Arbovirus IFA). However, cross-
reactivity of immune antibodies with closely related ﬂavivi-
ruses can impair the accuracy of the diagnosis and there is
a requirement for a ﬂuorescent microscope to evaluate the
results.
3.1.4. ELISA. ELISA is routinely used for the diagnosis of
WNV infection [140]. IgG- and IgM-capture (MAC-ELISA)
ELISAs for WNV were originally developed by the Centers
forDiseaseControl(CDC)andappliedtohumanandequine
WNV infection diagnosis [32, 141–143]. Prior to this, IgG
and IgM capture ELISAs were developed in the 1980s for
the detection of antibodies to JEV [29]. The MAC-ELISA
was developed to diagnose recent infections and involves
the capturing of test-serum IgM with immobilised anti-
species IgM, followed by the addition of WNV antigen and
detection with a ﬂavivirus-speciﬁc, horseradish peroxidase-
conjugated monoclonal antibody. The ﬁrst Food and Drug
Administration- (FDA-) cleared assay of this nature was de-
veloped by PanBio, who have since released improved ver-
sions with increased accuracy [144]. The persistence of IgM
from WNV infections [25, 27, 28] led to the development of
avidity testing, in order to improve the usability of ELISA for
diﬀerentiating past and recent infections [145]. Speciﬁcity
problems associated with ﬂavivirus cross-reactivity, have
been reduced through the application of algorithms [146].
The sensitivity and speciﬁcity of commercially available
ELISAs has been reviewed by Zhang et al. (2009) [147]. A
survey of public health and commercial diagnostic reference
laboratories in 2008 revealed that ELISA or microsphere im-
munoassay-based IgM and IgG assays were most commonly
used for the diagnosis of WNV infections, with signiﬁcantly
fewer laboratories using PCR, PRNT, and culture isolation
[148].
Deﬁned epitope blocking ELISAs have also been used
to increase the speciﬁcity of WNV serodiagnosis and have
been useful for diﬀerentiating ﬂaviviral infections through
targeting epitopes on NS1 [56, 58, 116]o rEp r o t e i n[ 149].
A recent study in horses has shown exquisite speciﬁcity
of the blocking ELISA originally published by Hall et al.
(1995)[56]whenassessingserumfromhorsesthathavebeen
sequentially infected with SLEV or DENV followed by WNV
[47]. The WNV blocking ELISA was positive only when
testing serum from the horses following exposure to WNV,
despite previous injection with SLEV or DENV. In contrast,
depending on the day, postinjection with WNV, PRNT and
IgM ELISA could not always be used to accurately diagnose
WNV as the most recent injected virus. Despite these data,
currentblockingELISAsareunabletodiﬀerentiateinfections
causedbydiﬀerentsubtypesofWNV[36]andfordiagnosing
WNV infection in patients who have received ﬂavivirus
vaccinations or have had previous ﬂaviviral infections [150].
Blocking ELISAs have been used extensively for surveillance
for WNV in North America [41, 151–154]a n df o rd e t e c t i o n
of KUNV and MVEV in Australia [36].
3.1.5. Immunoblot. Western blot using lysates of ﬂavivirus-
infected cell monolayers can potentially diﬀerentiate ﬂa-
viviral infections [89, 94]. In a study by Oceguera et al.
(2007) [94], where serum antibody reactivity to E, NS1, and
prM proteins of WNV and SLEV was analysed, NS1 was
most useful in diﬀerentiating WNV and SLEV infections
in humans, whereas prM was the most speciﬁc antigen for
diﬀerentiating JEV and DENV virus infections in a study
by Cardosa et al. (2002) [89]. Western blot using crude
lysates was also used to assess for the seroprevalence of
WNV in horses in sub-Saharan Africa [155]. A drawback to
using Western blot to analyse sera is that frequently serum
antibodies will also recognise other proteins within the cell
lysates and this can make accurate interpretation of the
results diﬃcult.Journal of Biomedicine and Biotechnology 5
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3.2. Recent Platform and Serological Assay Developments
3.2.1. High-Throughput, Rapid Microneutralisation Assays.
An automated colorimetric microneutralization assay has
recently been described for the detection of, and diﬀer-
entiation between, WNV and SLEV infections in humans
[156]. Of the 152 PRNT-conﬁrmed negative, WNV-positive
orSLEV-positivesera,therewasconcordancebetweenPRNT
andtherapidmicroneutralisationassayforallsamplesexcept
one. The advantages of this assay over traditional PRNT
are that the testing duration is signiﬁcantly reduced and
the assay can be performed in a 96-well format, enabling 8
dilutions of each sample to be analysed simultaneously. Like
PRNT, neutral red is used to stain live cells; however, in this
automated assay, the stained live cells are solubilised and the
optical density quantiﬁed using a plate reader. The obvious
drawback to this assay is that the handling of live virus is still
a necessity.
3.2.2. Lateral Flow. The FDA has recently approved a lateral
ﬂow device for the diagnosis of WNV infection in humans
[133]. This assay has signiﬁcant advantages over ELISA
(which can take several hours to perform) in that a result
is obtained within 15 minutes [157]. Lateral ﬂow assays
routinely consist of antigens or antibodies immobilised on
nitrocellulose strips and utilise gold particles or coloured
latex as reporter molecules. The assay is commonly housed
in a plastic or cardboard cassette. In the case of the WNV
lateralﬂowassay,anti-WNVIgMantibodiesinpatientserum
form a tertiary complex with biotinylated anti-human IgM,
recombinant WNV E protein, and an anti-E mAb which
is coupled to colloidal gold particles. This complex is then
captured by immobilised streptavidin on the nitrocellulose
strip to form a pink line. This assay displayed 98.8% sensi-
tivity and 95.3% speciﬁcity, as compared to other predicate
assays [133]. However, such devices are most suitable for
situations where only a small number of tests are to be
performed and where qualitative results are acceptable.
3.2.3.MicrosphereImmunoassay(MIA). Microsphereimmu-
noassay (MIA) is a bead-based microﬂuidic system in which
an antigen is attached to encoded microbeads that can be
identiﬁed using a ﬂuorescence-activated cell sorting system
(FACS). Target analytes that bind the beads during the assay
procedure are detected using a ﬂuorescent molecule. MIA
oﬀers two advantages over other serological assays such as
ELISA: ﬁrstly, it is possible to multiplex the assay such that
one serum can be assessed for reactivity to many antigens in
a single run. Secondly, MIA oﬀers higher sensitivity through
the use of ﬂuorescence [158]. In one study using MIA, WNV
NS3 and NS5 antigens were assessed for the speciﬁc detec-
tion of recent WNV infections and to diﬀerentiate those
patients that had been vaccinated against ﬂaviviral infection
[63]. The NS5 MIA showed 92% sensitivity (n = 61) for
PRNT-conﬁrmed WNV positive samples that were collected
7 to 77 days postsymptom onset, while none of the samples
from JEV-vaccinated individuals were positive and only
5% of the samples from YFV vaccinated individuals were
positive, indicating good diagnostic speciﬁcity of the assay.
Further, when assessed for cross-reactivity with DENV- and
SLEV-positive samples, there was 9% and 5% false positives
observed, respectively, for the NS5 MIA. At the time of this
study’s publication, it was thought that NS5 could be used to
detect antibodies from patients with recent WNV infections;
however, a subsequent comprehensive study using the same
platformshowedthat77%ofseratestedshowedthepresence
of anti-NS5 antibodies after 90 days and 13% of patients
retained anti-NS5 antibodies after one year [64].
The MIA platform also enabled the simultaneous assess-
ment and validation of various WNV antigens for the detec-
tion of WNV antibodies in horse sera [159] and has also
been validated for the detection of anti-WNV and anti-SLEV
IgM antibodies in human serum [134]. Rather than NS3 or
NS5 antigen, this assay is based on the reactivity of serum
antibodies to antigen captured by the anti-E monoclonal
antibody, 6B6C-1 [134]. Many laboratories in the USA have
adopted this assay for WNV diagnosis [134, 148]. One
obvious drawback of the MIA platform is the requirement
for expensive, specialised equipment.
3.2.4. Biosensors and Microﬂuidic Systems. The design of
biosensors and microﬂuidic devices is targeted to ﬁeld use
andpointofcare.Somearebasedondipstickandlateralﬂow
formats, while other newer concepts use microcapillaries
to direct the ﬂow of biological samples and assay reagents
through various chambers in the device. However, these
are just two examples of platforms which fall into this
category. In terms of advances in ﬂaviviral research in this
area,Teles(2011)providesacomprehensivecriticalreviewof
biosensor-based assays for the diagnosis of Dengue infection
[160]. Similarly a microﬂuidic system based on virus-coated
magnetic beads for the detection of IgM and IgG antibodies
against DENV within 30 minutes has been described by Lee
et al., (2009) [161].
In terms of advances in WNV diagnosis using biosensors
and microﬂuidic systems, a linear, 15 amino acid fragment
of domain III of WNV was successfully used as an antigen on
an amperometric immunosensor [162] .I nas e c o n ds t u d y ,a
surfaceenhancedRamanscatteringimmunoassaywasshown
to be highly sensitive for the detection of anti-WNV immu-
noglobulin [163]. Using gold particles coated with WNV E
protein, this assay was capable of detecting 50pg/mL anti-
WNV E immunoglobulin in rabbit serum, which is 400
times more sensitive than a standard direct sandwich ELISA.
However, this assay still requires validation with clinical or
ﬁeld sera.
3.2.5. Autologous Red Blood Cell Agglutination Assays. While
not a new technology, the autologous red blood cell (RBC)
agglutination assay platform has only recently been assessed
in a pilot study for the detection of antibodies to WNV.
This technology was patented in the early 1990’s by AGEN
Biomedical Ltd. and had considerable advantages over tra-
ditional haemagglutination assays, ELISA and radioimmu-
noassays due to its ease of use and speed in which speciﬁc
and sensitive diagnosis could be made [164, 165]. OriginallyJournal of Biomedicine and Biotechnology 7
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Peptide
Patient antipeptide
antibody 
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Figure 1: Autologous agglutination assay. Agglutination of RBC’s
(b, d) by the crosslinking of the assay reagent (c) and blood-borne
antipeptide antibodies. Agglutination does not occur in nonim-
mune samples (a).
developedforthedetectionofanti-HIVantibodies inpatient
serum, the RBC agglutination assay reagent comprised a
mAb with high aﬃnity to human RBCs, chemically coupled
to a speciﬁc viral antigen [164, 166, 167]. When a drop of
infected patient blood was mixed with the mAb-peptide fu-
sion protein, within two minutes, visible agglutination oc-
cured [164, 166, 167]( Figure 1).
The advantages of this agglutination assay technology are
many. It is rapid, portable and minimises sample handling.
Because the read-out system is the patient’s own eryth-
rocytes, there is no need for secondary reagents such as ﬂu-
orophore- or gold-labelled antibodies, reagent-coated latex
beads or ﬁxed heterologous erythrocytes. Further, this assay
requires minimal training, specialised equipment, electricity
or running water, making it useful for emergency testing,
ﬁeld surveillance testing, mass screening and use in develop-
ing countries [164, 167–169]. A functional RBC agglutina-
tion assay requires the manufacture of only one component
comprised of two biologicals—a peptide and an antibody
fragment. In contrast, lateral-ﬂow diagnostics require the
optimisation and validation of gold-conjugation technolo-
gies and the striping of biologicals onto membranes. These
processes are more technically—and time—demanding.
Several groups have explored the production of autolo-
gous RBC agglutination reagents by recombinant methods
[168, 170–174]. The feasibility of this approach was initially
established in a bacterial expression system that used a single
chain Fv fragment (scFv) derived from the original anti-
erythrocyte mAb recombinantly fused to the HIV peptide
[170, 171]. Although functional reagents were produced, the
recovery of the reagent required extensive extraction and
puriﬁcation procedures. We recently described the secreted
expression of the human-based recombinant autologous
agglutination reagent in mammalian cells, as both single
chain (scFv) and intact mAbs [175]. The anti-RBC antibody
was fused to a WNV diagnostic tag (WN19) and was shown
to be functional in agglutination assays and suitable for diag-
nosis of WNV infection in horses. However, the reagent was
not expressed at high enough levels within the cell culture
medium for the true potential of this assay system to be
realised.Inparticular,weaimedtodevelopasystembasedon
generic vectors into which antigenic peptides could rapidly
be incorporated and one in which the culture supernatant
could be used for agglutination reactions without further
processing. Recombinant expression of these agglutination
reagents would enable rapid, on-demand production for
minimal cost. This is particularly important for developing
countries where outbreaks of new pathogens are frequent
and there is a requirement for inexpensive, “point-of-care”
assays.
4.AntigenFormulationsto
ImproveAssaySpeciﬁcity
The speciﬁcity of serological assays for the diagnosis of
ﬂaviviral infections predominantly relies on the antigen used
intheassay.Anumberofalternativeantigenstothecomplete
E protein or total viral antigen have been assessed in recent
years, particularly for improving the speciﬁcity of WNV
seroassays. Some of these studies are listed in Table 2.
4.1. E Protein. The ﬂaviviral E protein is frequently used in
serological diagnostic assays [176]. However, some E protein
epitopes induce ﬂavivirus cross-reactive antibodies [66, 78]
and recent attempts to improve the speciﬁcity of assays using
E protein-based antigens have focused on using peptides
or individual domains of the E protein [136–138]. By
eliminating the cross-reactive epitopes in the E protein DII,
Roberson et al. (2007) reported a WNV diagnostic antigen
that conferred considerably higher speciﬁcity to diagnostic
assays than its wild-type counterpart [136], reducing the
number of false positives by 21-22%. In a diﬀerent approach,
Beasley et al. (2004) developed a recombinant protein based
on the E protein DIII (EDIII). When the EDIII subunit
protein was used in ELISA, there was clear discrimination
of WNV-immune mouse ascitic ﬂuid from mouse immune
ascitic ﬂuids generated against JEV, MVEV, SLEV, DENV
and YFV [137]. While the EDIII ELISA displayed strong
correlation with HI and PRNT for the detection of anti-
WNV IgG in ﬁeld trials with monkey, horse, and human
sera, the speciﬁcity of the ELISA was not challenged with
sera obtained from natural infections with other ﬂaviviruses
of the JEV serocomplex. In a more deﬁned analysis of DIII
antigens, a linear, 15-amino-acid fragment of this domain
was successfully used in ELISA [138]f o rh u m a nW N V
infection diagnosis and has also been assessed as an antigen
on an amperometric immunosensor [162]. The comparative
speciﬁcity of these E protein subunit antigens has not been
fully investigated. However, in the ELISA, 100% speciﬁcity
and 67% sensitivity was achieved when compared with a
commercial WNV IgG ELISA kit.8 Journal of Biomedicine and Biotechnology
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Our laboratory has identiﬁed a peptide (WN19) in Do-
main I of the E protein which has been successfully trialled
in a small ﬁeld study for the detection of anti-WNV antibod-
ies in horse sera using Western blot [60, 61]. The peptide
WN19 sequence encompasses the WNV envelope protein
glycosylation site at position 154 and it was shown that the
carbohydrate moiety was required for recognition of peptide
WN19 by most WNV-immune horse sera assessed. The dis-
advantage of compartmentalising any target antigen is that
there is often a reduction in sensitivity. This is evidenced by
our data where a number of samples with VNT titres ≥160
reacted only weakly with peptide WN19, or not at all [60]. In
Western blot, peptide WN19 was also detected by horse sera
containing MVEV-neutralising antibodies.
4.2. prM. The prM antigen has been successfully used to dif-
ferentiate DENV and JEV infections in humans using West-
ern blot [89]. Western blot analysis has also shown that prM
is consistently recognised by WNV-immune horse serum
[62]. An obstacle to the use of the prM antigen for diﬀer-
entiating ﬂaviviral infections is a diﬃculty in expressing a
correctly folded protein. High-level expression of membrane
proteins is inherently diﬃcult and compartmentalising the
prM protein so that only the soluble pr peptide is expressed,
results in the elimination of the epitope(s) recognised by
WNV-immune serum [62]. A detailed analysis on the use of
prM to diﬀerentiate infections caused by viruses of the JEV
serogroup is yet to be published.
A continuous JEV prM/M peptide that is recognised by
anti-JEV rabbit serum and not by anti-WNV or -DENV se-
rum has also been identiﬁed. However, the eﬃcacy of this
peptide in assays with clinical sera is yet to be determined
[139].
5. Conclusions
The continued spread of ﬂaviviruses worldwide warrants
the need for rapid serological assays of increased speciﬁcity.
In countries such as Australia, where multiple arboviruses
infecting horses and humans can cocirculate, as well as the
increased prevalence of other encephalitic-disease causing
virusessuchasHendra,thereisaneedforthedevelopmentof
rapid,pen-sideimmunoassays.WhileELISAisidealforhigh-
throughput testing, this assay format is not suitable for rapid
point of care and veterinary pen-side testing. The develop-
ment of rapid, portable ﬂavivirus immunoassays has been
impaired by the cross-reactive immune response generated
against these pathogens in vertebrates. The diﬃculty lies in
identifying a single antigen that confers both high sensitivity
and speciﬁcity to the immunoassay. Multiplex assays such as
MIA are ideal for giving an accurate proﬁle of the immune
response against various ﬂaviviral antigens simultaneously.
It is feasible that this platform could be used to test serum
samples against NS3, NS5, E domain subunits such as DIII
and the DI WN19 peptide, NS1 and prM in a single assay.
However, application of ﬂaviviral antigens to a multiplexed
rapid, point-of-care device such as lateral ﬂow has not yet
been reported. Devices for multiplexed ABO blood typing
agglutination assays such as the patented EldonCard system
or microﬂuidic device [177] may be readily adaptable for
use with the autologous agglutination system, particularly
if larger ﬂaviviral antigens such as E DIII or NS1 can be
recombinantly fused to the RBC-binding antibody.
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